Accessibility Menu
Eisai logo

Eisai(OTC) ESALF

Current Price$26.18
Market Cap$7.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+38%
5 Year-68%
1 Year-0%
1 Month+5%
Eisai last closing stock price
MetricPriceDate
Last closeUSD 26.182026-07-20
Eisai stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 26.182026-07-13
1 month+4.7%USD 25.002026-06-17
3 month-11.26%USD 29.502026-04-17
Year to date-10.44%USD 29.232025-12-31
1 year-0.35%USD 26.272025-07-18
3 year-56.35%USD 59.972023-07-21
5 year-68.28%USD 82.512021-07-16
Since inception+38.42%USD 18.912003-07-17

Eisai Financials at a Glance

Market Cap

$7.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥830.66B

Net Income (TTM)

¥38.77B

EPS (TTM)

$0.92

P/E Ratio

28.42

Dividend

$1.04

Beta (Volatility)

0.08 (Low)

Price

$26.18

Volume

15

Open

$26.18

Previous Close

$26.18

Daily Range

$26.18 - $26.18

52-Week Range

$23.88 - $35.83

Estimated Earnings Date

Aug 3, 2026

ESALF News

Scale

FDA Asks That Weight Loss Drug Belviq Be Pulled From the Market

Brian Orelli, PhDFeb 13, 2020
AD

Why Biogen Stock Is Crashing Today

George Budwell, PhDMar 21, 2019
Alz

Why Biogen's Stock Is Slumping Today

George Budwell, PhDJul 26, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eisai

Eisai Co., Ltd. is a pharmaceutical company based in Tokyo, Japan, specializing in the development and marketing of a diverse range of medicinal products. The company focuses on neurological conditions and oncology, providing innovative treatments that address significant health challenges.

Products and Services
  • Aricept for Alzheimer's disease and dementia
  • Lenvima, a targeted therapy for various cancers
  • Consumer health products like Chocola BB Plus
Growth Outlook
  • Strong pipeline with multiple new drug candidates in development
  • Expansion into emerging markets to drive revenue growth
  • Increased focus on research and development to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 206.72 billion JPY, showing resilience
  • Trailing twelve months (TTM) revenue of 1.01 trillion JPY
  • Dividend yield of 4.05%, reflecting commitment to shareholder returns
Eisai Co., Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the treatment of neurological disorders and cancer. The company's flagship products, such as Aricept and Lenvima, have garnered significant market attention, contributing to a robust revenue stream. Recent financial data indicates a quarterly revenue of 206.72 billion JPY, demonstrating the company's ability to maintain stability in a competitive market. The trailing twelve months (TTM) revenue of 1.01 trillion JPY further underscores the company's strong performance. Additionally, Eisai's commitment to returning value to shareholders is evident through a dividend yield of 4.05%. The company is actively pursuing growth opportunities, including expanding its presence in emerging markets and investing in research and development to enhance its product portfolio. Overall, Eisai Co., Ltd. presents a compelling opportunity for investors interested in the pharmaceutical sector, with a focus on innovative treatments and a solid financial foundation.
AI Generated • Jun 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,543

CEO

Haruo Naito

Website

www.eisai.co.jp/index.html

Headquarters

Tokyo, TY 112-8088, JP

ESALF Financials

Key Financial Metrics (TTM)

Gross Margin

76.83%

Operating Margin

4.87%

Net Income Margin

4.67%

Return on Equity

4.44%

Return on Capital

3.71%

Return on Assets

2.66%

Earnings Yield

3.52%

Dividend Yield

3.99%

Payout Ratio

1.17%

Stock Overview

Market Cap

$7.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

282.11M

Volume

15

Avg. Volume

424.307

Financials (TTM)

Gross Profit

¥638.21B

Operating Income

¥40.42B

EBITDA

¥92.77B

Operating Cash Flow

¥61.69B

Capital Expenditure

-¥15.45B

Free Cash Flow

¥46.24B

Cash & ST Invst.

¥246.97B

Total Debt

¥187.25B

Eisai Performance Analysis

Eisai annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 5,495,248,038-18.3%
20242024-03-31JPY 5,136,302,320-6.5%
20252025-03-31JPY 5,178,078,7190.8%
20262026-03-31JPY 5,477,248,5255.8%
Eisai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3011.6%
Q22025-09-30-1.7%
Q32025-12-3110.0%
Q42026-03-31-6.1%
Eisai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.43-4.1%
20242024-03-31JPY 1.02-28.3%
20252025-03-31JPY 1.074.9%
20262026-03-31JPY 0.91-15.5%
Eisai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-301452.2%
Q22025-09-30-29.8%
Q32025-12-3166.9%
Q42026-03-31-119.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

¥206.72B

+13.3%

Gross Profit

¥154.38B

+7.9%

Gross Margin

74.68%

N/A

Market Cap

$7.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$700.40K

N/A

Employees

10,543

N/A

Net Income

-¥3.27B

-455.4%

EBITDA

-¥84.53M

-100.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

¥246.97B

-7.2%

Total Debt

¥187.25B

-0.1%

Accounts Receivable

¥228.43B

+3.8%

Inventory

¥259.17B

+20.0%

Long Term Debt

¥135.63B

+35.9%

Short Term Debt

¥51.63B

-41.1%

Return on Assets

2.66%

N/A

Return on Invested Capital

3.63%

N/A

Free Cash Flow

-¥954.97M

-103.8%

Operating Cash Flow

¥4.12B

-85.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
GIFLFGrifols, S.A.
$10.25+0.00%
WILYYDemant A/S
$20.66+0.00%
WILLFDemant A/S
$41.51+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About ESALF

What is the current price of Eisai?

Eisai is trading at $26.18 per share.

What is the 52-week range for Eisai?

Over the past 52 weeks, Eisai has traded between $23.88 and $35.83.

How much debt does Eisai have?

As of the most recent reporting period, Eisai reported total debt of ¥1.44B.

How much cash does Eisai have on hand?

Eisai reported ¥1.54B in cash and cash equivalents in its most recent financial results.

What is Eisai’s dividend yield?

Eisai currently has a dividend yield of 3.99%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services